FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Sara Grethlien, MD, MBA, FACP, Swedish Cancer Institute, looks ahead to the future of oncology care and important value-based care considerations.

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic ...

Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who ...

This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of ...

According to Ian Neeland, MD, strategies like pharmacist-led counseling, patient education programs, and patient assistance ...

The individual behavior of a patient’s myeloproliferative neoplasm (MPN) will determine how the disease is monitored and ...

Edgardo S. Santos, MD, FACP, FASCO, highlighted how liquid biopsies are transforming lung cancer care by enabling faster, ...

Top articles about HIV this year included effects of HIV on tooth loss and cardiac surgery, caregiver experiences, and a ...

Panelists discuss how alopecia areata (AA) presents with hallmark symptoms such as sudden hair loss, and how the condition fluctuates over time, making it a relapsing or remitting inflammatory disease ...

Ryan Nguyen, DO, University of Illinois Chicago, highlights the importance of personalized care for patients who have non–small cell lung cancer (NSCLC) and the potential of artificial intelligence ...

Markey Cancer Center combats clinical trial misconceptions by emphasizing standard care and changing terminology to improve ...